Vivos Therapeutics (VVOS) Retained Earnings (2019 - 2026)

Vivos Therapeutics (VVOS) has reported Retained Earnings for 8 consecutive years, with -$138.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Retained Earnings fell 217.74% year-over-year to -$138.5 million in Q2 2026; TTM through Jun 2026 was -$138.5 million, a 217.74% decrease from a year earlier, with the FY2025 full-year figure at -$125.4 million, down 211.79% from the prior year.
• Retained Earnings was -$138.5 million for Q2 2026 at Vivos Therapeutics, down from -$133.0 million in the prior quarter.
• Over five years, Retained Earnings peaked at $121.0 million in Q3 2025 and troughed at -$138.5 million in Q2 2026.
• A 5-year average of $59.4 million and a median of $88.8 million in 2023 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings surged 54.49% in 2022 and sank 218.3% in 2026, its largest moves.
• Over 5 years, Retained Earnings stood at $84.3 million in 2022, then advanced by 10.91% to $93.5 million in 2023, then gained by 19.99% to $112.1 million in 2024, then sank by 211.79% to -$125.4 million in 2025, then declined by 10.5% to -$138.5 million in 2026.
• The last three Retained Earnings figures came in at -$138.5 million (Q2 2026), -$133.0 million (Q1 2026), and -$125.4 million (Q4 2025), per Business Quant data.